Risk of AML Evolution In Lower Risk MDS with Del 5q Treated with or without Lenalidomide. A Report by the Groupe Francophone Des Myelodysplasies (GFM)

被引：0
|
作者：
Ades, Lionel [1 ]
Lebras, Fabien [1 ]
Sebert, Marie [1 ]
Kelaidi, Charikleia [1 ]
Lamy, Thierry [1 ]
Dreyfus, Francois [1 ]
Delaunay, Jacques [1 ]
Visanica, Sorin [1 ]
Turlure, Pascal [1 ]
Guerci, Agnes [1 ]
Cabrol, Marie Paule [1 ]
Banos, Anne [1 ]
Blanc, Michel [1 ]
Vey, Norbert [1 ]
Eclache, Virginie [1 ]
Chevret, Sylvie [1 ]
Fenaux, Pierre [1 ]
机构：
[1] Grp Francophone Myelodysplasies GFM, Bobigny, France
来源：
BLOOD | 2010年 / 116卷 / 21期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
下载
收藏
页码：429 / 430
页数：2
相关论文
共 50 条
  • [21] Clonal Effect Of Lenalidomide On Akt Activation In Low-Risk MDS Patients With Del(5q)
    Follo, Matilde Y.
    Finelli, Carlo
    Clissa, Cristina
    Mongiorgi, Sara
    Baldazzi, Carmen
    Stanzani, Marta
    Baccarani, Michele
    Cocco, Lucia
    BLOOD, 2013, 122 (21)
  • [22] A Phase II Study of the Efficacy and Safety of an Intensified Schedule of Azacitidine (AZA) in Intermediate-2 and High Risk MDS Patients: A Study By the Groupe Francophone Des Myelodysplasies (GFM)
    Ades, Lionel
    Guerci-Bresler, Agnes
    Cony-Makhoul, Pascale
    Legros, Laurence
    Sebert, Marie
    Braun, Thorsten
    Delaunay, Jacques
    Samey, Benedicte
    Desseaux, Kristell
    Chevret, Sylvie
    Fenaux, Pierre
    BLOOD, 2015, 126 (23)
  • [23] Polish experience of lenalidomide in the treatment of lower risk myelodysplastic syndrome with isolated del(5q)
    Butrym, Aleksandra
    Lech-Maranda, Ewa
    Patkowska, Elzbieta
    Kumiega, Beata
    Bieniaszewska, Maria
    Mital, Andrzej
    Madry, Krzysztof
    Torosian, Tigran
    Wichary, Ryszard
    Rybka, Justyna
    Warzocha, Krzysztof
    Mazur, Grzegorz
    BMC CANCER, 2015, 15
  • [24] Polish experience of lenalidomide in the treatment of lower risk myelodysplastic syndrome with isolated del(5q)
    Aleksandra Butrym
    Ewa Lech-Maranda
    Elżbieta Patkowska
    Beata Kumiega
    Maria Bieniaszewska
    Andrzej Mital
    Krzysztof Madry
    Tigran Torosian
    Ryszard Wichary
    Justyna Rybka
    Krzysztof Warzocha
    Grzegorz Mazur
    BMC Cancer, 15
  • [25] Treatment of lower risk MDS with del 5q by lenalidomide (LEN), with or without G-CSF: current results of the French Patient Named Program (ATU)
    Sebert, M.
    Le Bras, F.
    Lamy, T.
    Dreyfus, F.
    Bannos, A.
    Blanc, M.
    Vey, N.
    Gardembas, M.
    Baudurer, F.
    Turlure, P.
    Beyne-Rauzy, O.
    Guercy, A.
    Fenaux, P.
    Ades, L.
    LEUKEMIA RESEARCH, 2009, 33 : S125 - S126
  • [26] Clinical characteristics and outcomes according to age in lenalidomide-treated patients with RBC transfusion-dependent lower-risk MDS and del(5q)
    Pierre Fenaux
    Aristoteles Giagounidis
    Dominik Selleslag
    Odile Beyne-Rauzy
    Moshe Mittelman
    Petra Muus
    Stephen D. Nimer
    Eva Hellström-Lindberg
    Bayard L. Powell
    Agnes Guerci-Bresler
    Mikkael A. Sekeres
    H. Joachim Deeg
    Consuelo del Cañizo
    Peter L. Greenberg
    Jamile M. Shammo
    Barry Skikne
    Xujie Yu
    Alan F. List
    Journal of Hematology & Oncology, 10
  • [27] Clinical characteristics and outcomes according to age in lenalidomide-treated patients with RBC transfusion-dependent lower-risk MDS and del(5q)
    Fenaux, Pierre
    Giagounidis, Aristoteles
    Selleslag, Dominik
    Beyne-Rauzy, Odile
    Mittelman, Moshe
    Muus, Petra
    Nimer, Stephen D.
    Hellstrom-Lindberg, Eva
    Powell, Bayard L.
    Guerci-Bresler, Agnes
    Sekeres, Mikkael A.
    Deeg, H. Joachim
    del Canizo, Consuelo
    Greenberg, Peter L.
    Shammo, Jamile M.
    Skikne, Barry
    Yu, Xujie
    List, Alan F.
    JOURNAL OF HEMATOLOGY & ONCOLOGY, 2017, 10
  • [28] EFFECT OF LENALIDOMIDE EXPOSURE ON RESPONSE AND OUTCOMES IN PATIENTS WITH LOWER-RISK NON-DEL(5Q) MYELODYSPLASTIC SYNDROMES (MDS)
    Garcia-Manero, G.
    Santini, V.
    Almeida, A.
    Fenaux, P.
    Gattermann, N.
    Ozawa, K.
    Goldberg, S. L.
    Weaver, J.
    Sugrue, M. M.
    LEUKEMIA RESEARCH, 2017, 55 : S51 - S51
  • [29] Disease progression in del(5q) MDS patients treated with lenalidomide: Analysis of risk factors and long term outcome in 45 patients
    Giagounidis, A.
    Haase, S.
    Lohrbacher, V.
    Schuran, B.
    Heinsch, M.
    Aul, C.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2007, 92 : 85 - 85
  • [30] Validation of the IPSS-R in lenalidomide-treated, lower-risk myelodysplastic syndrome patients with del(5q)
    M A Sekeres
    A S Swern
    P Fenaux
    P L Greenberg
    G F Sanz
    J M Bennett
    F Dreyfus
    A F List
    J S Li
    M M Sugrue
    Blood Cancer Journal, 2014, 4 : e242 - e242
12345